You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝康醫療-B(2170.HK):獲中金維持“跑贏行業”評級,看好核心產品PGT-A放量
格隆匯 09-02 08:52
格隆匯9月2日丨貝康醫療-B(2170.HK)8月30日發佈中報業績顯示,2021年上半年營收5016.2萬元,同比增56%;毛利2215.5萬元,同比增94.3%;毛利率44.17%,同比提升8.72ppt;淨虧損4209萬元。中金8月31日發佈業績點評稱,貝康醫療上半年收入快速增長,毛利率明顯提升,主要是上半年公司核心產品PGT-A試劑盒毛利率達到71%,帶動整體毛利率提升所致。目前公司已與44家醫院簽訂了關於PGT-A試劑盒的合作協議。鼓勵生育的大背景下,隨着拿到PGT許可證生殖診所變多以及貝康進駐生殖診所家數變多,看好PGT-A放量。公司在研管線豐富,除已獲批的PGT-A試劑盒外,公司正開發另外兩款基因檢測產品,分別是PGT-M和PGT-SR,用以共同佔據PGT領域,預計分別會在2022年和2024年獲批,中金預計貝康醫療2022年或將扭虧為盈,維持“跑贏行業”評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account